May Health is developing a modern treatment - Ovarian Rebalancing - designed to restore ovulation for people with polycystic ovary syndrome.
Total raised: $25M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.05.2024 | Series B | $25M | Trill Impa... |
Mentions in press and media 5
| Date | Title | Description |
| 14.05.2024 | May Health Secures $25M to Revolutionize PCOS Treatment | May Health, a Paris-based medical device company, recently closed a $25M Series B funding round led by Bpifrance and Trill Impact Ventures. The funding will propel the development of their innovative Ovarian Rebalancing™ therapy, aimed at a... |
| 13.05.2024 | May Health grabs $25m Series B | - |
| 13.05.2024 | Trill Impact Ventures co-leads USD 25 million series B financing round in May Health | Trill Impact Ventures co-leads USD 25 million series B financing round in May Health Mon, May 13, 2024 14:00 CET Report this content Advancing novel treatment for women suffering from Polycystic Ovary Syndrome related infertility. Trill Imp... |
| 13.05.2024 | May Health Raises $25M in Series B Funding | May Health, a Paris, France-based clinical-stage medical device company, raised $25M in Series B funding. The round was led by Bpifrance and Trill Impact with participation from founding investor Sofinnova Partners, as well as Avestria Vent... |
| 13.05.2024 | May Health raises $25M to address PCOS-related infertility | The company has developed Ovarian Rebalancing, a one-time, in-office procedure to induce ovulation Polycystic ovary syndrome (PCOS) is a lifelong endocrine disorder that affects 10% of women around the world, and can cause excess body hair,... |